Patent ID: 11925663
Assignee: ATARA BIOTHERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 19:
20. In a method of treating a solid malignant tumor in a human patient that comprises administering to the human patient a population of human cells comprising antigen-specific T cells that are specific for one or more antigens of the solid malignant tumor, said antigen-specific T cells having been generated by ex vivo sensitizing human T cells to the one or more antigens, wherein the antigen-specific T cells are not genetically engineered to be specific for the one or more antigens, wherein the population of human cells contains at least 70% T cells, and wherein the solid malignant tumor is a lymphoma, wherein the improvement comprises: (a) monitoring the human patient for an indication of tumor flare, wherein the tumor flare is a clinical reaction to the administration of the population of human cells that is manifested as swelling of the tumor; (b) grading tumor flare in the human patient as Grade 2, 3, or 4 according to the Evaluation column in the following Table; and (c) managing tumor flare in the human patient according to the Intervention column in the following Table:, Tumor Flare

Severity
Evaluation
Intervention

Grade 2
Symptomatic; medical 
Medical treatment

intervention indicated

Grade 3
Stridor, respiratory 
Hospitalization with 

distress; hospitalization 
monitoring as appropriate 

indicated
for the anatomic tumor site

Grade 4
Life-threatening airway 
Intubation to protect the 

compromise; urgent 
airway if appropriate; other 

intervention indicated
intervention according to 

the anatomic tumor site.